Literature DB >> 22824630

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

Robert C Kalayjian1, Bryan Lau, Rhoderick N Mechekano, Heidi M Crane, Benigno Rodriguez, Robert A Salata, Zipporah Krishnasami, James H Willig, Jeffrey N Martin, Richard D Moore, Joseph J Eron, Mari M Kitahata.   

Abstract

OBJECTIVE: To examine long-term effects of antiretroviral therapy (ART) on kidney function, we evaluated the incidence and risk factors for chronic kidney disease (CKD) among ART-naive, HIV-infected adults and compared changes in estimated glomerular filtration rates (eGFR) before and after starting ART.
METHODS: Multicenter observational cohort study of patients with at least one serum creatinine measurement before and after initiating ART. Cox proportional hazard models, and marginal structure models examined CKD risk factors; mixed-effects linear models examined eGFR slopes.
RESULTS: Three thousand, three hundred and twenty-nine patients met entry criteria, contributing 10 099 person-years of observation on ART. ART was associated with a significantly slower rate of eGFR decline (from -2.18 to -1.37 ml/min per 1.73 m per year; P = 0.02). The incidence of CKD defined by eGFR thresholds of 60, 45 and 30 ml/min per 1.73 m was 10.5, 3.4 and 1.6 per 1000 person-years, respectively. In adjusted analyses black race, hepatitis C coinfection, lower time-varying CD4 cell count and higher time-varying viral load on ART were associated with higher CKD risk, and the magnitude of these risks increased with more severe CKD. Tenofovir and a ritonavir-boosted protease inhibitor (rPI) was also associated with higher CKD risk [hazard odds ratio for an eGFR threshold <60 ml/min per 1.73 m: 3.35 (95% confidence interval (CI) = 1.40-8.02)], which developed in 5.7% of patients after 4 years of exposure to this regimen-type.
CONCLUSION: ART was associated with reduced CKD risk in association with CD4 cell restoration and plasma viral load suppression, despite an increased CKD risk that was associated with initial regimens that included tenofovir and rPI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824630      PMCID: PMC3531628          DOI: 10.1097/QAD.0b013e328357f5ed

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  49 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

3.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

4.  Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

Authors:  Amit C Achhra; Janaki Amin; Matthew G Law; Sean Emery; Jan Gerstoft; Fred M Gordin; Michael J Vjecha; James D Neaton; David A Cooper
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

5.  Protease inhibitors are associated with a slowed progression of HIV-related renal diseases.

Authors:  L A Szczech; L J Edwards; L L Sanders; C van der Horst; J A Bartlett; A E Heald; L P Svetkey
Journal:  Clin Nephrol       Date:  2002-05       Impact factor: 0.975

6.  Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy.

Authors:  Christopher J Cosgrove; Ali K Abu-Alfa; Mark A Perazella
Journal:  Am J Med Sci       Date:  2002-02       Impact factor: 2.378

7.  Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.

Authors:  Frédéric-Antoine Dauchy; Sylvie Lawson-Ayayi; Renaud de La Faille; Fabrice Bonnet; Claire Rigothier; Nadia Mehsen; Ghada Miremont-Salamé; Charles Cazanave; Carine Greib; Francois Dabis; Michel Dupon
Journal:  Kidney Int       Date:  2011-05-04       Impact factor: 10.612

8.  Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.

Authors:  Ursula C Brewster; Mark A Perazella
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

9.  The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.

Authors:  Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

10.  Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.

Authors:  Gregory M Lucas; Joseph A Eustace; Stephen Sozio; Evelyn K Mentari; Kofi A Appiah; Richard D Moore
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

View more
  56 in total

Review 1.  Antiretroviral therapy: current drugs.

Authors:  Alice K Pau; Jomy M George
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  Thirty-day hospital readmissions for adults with and without HIV infection.

Authors:  S A Berry; J A Fleishman; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2015-07-14       Impact factor: 3.180

Review 3.  Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.

Authors:  Shibing Yang; Charles B Eaton; Juan Lu; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-24       Impact factor: 2.890

4.  Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database.

Authors:  Jason Cheung; Rainer Puhr; Kathy Petoumenos; David A Cooper; Ian Woolley; Manoji Gunathilake; Nigel Raymond; Rick Varma; Catherine C O'Connor; David M Gracey
Journal:  Nephrology (Carlton)       Date:  2018-08       Impact factor: 2.506

Review 5.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

6.  Markers of renal disease and function are associated with systemic inflammation in HIV infection.

Authors:  S K Gupta; D Kitch; C Tierney; K Melbourne; B Ha; G A McComsey
Journal:  HIV Med       Date:  2015-05-20       Impact factor: 3.180

7.  JC polyoma viruria associates with protection from chronic kidney disease independently from apolipoprotein L1 genotype in African Americans.

Authors:  Barry I Freedman; Amy L Kistler; Peter Skewes-Cox; Don Ganem; Mitzie Spainhour; Jolyn Turner; Jasmin Divers; Carl D Langefeld; Mariana Murea; Pamela J Hicks; Ashok K Hemal; James A Snipes; Lihong Zhao; Johanna R Abend; Douglas S Lyles; Lijun Ma; Karl L Skorecki
Journal:  Nephrol Dial Transplant       Date:  2018-11-01       Impact factor: 5.992

8.  Organ Transplantation and HIV Progress or Success? A Review of Current Status.

Authors:  Alan Taege
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

9.  Thirty-day hospital readmission rate among adults living with HIV.

Authors:  Stephen A Berry; John A Fleishman; Baligh R Yehia; P Todd Korthuis; Allison L Agwu; Richard D Moore; Kelly A Gebo
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

10.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.